The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy
Shinno, Yuki, Goto, Yasushi, Ohuchi, Mayu, Hamada, Akinobu, Nokihara, Hiroshi, Fujiwara, Yasuhiro, Ohe, YuichiroVolume:
1
Journal:
JTO Clinical and Research Reports
DOI:
10.1016/j.jtocrr.2020.100008
Date:
March, 2020
File:
PDF, 625 KB
2020